Macquarie Group
BCLI

Macquarie Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Macquarie Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-296
Closed -$21K – 2361
2020
Q1 		$21K Buy
+296
New +$23.1K ﹤0.01% 1914

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Macquarie Group's BCLI Position: Q2 2020 in Review

Macquarie Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2020, closing a stake of 296 shares — an estimated $21K sold.

Macquarie Group first reported a position in BCLI in Q1 2020 and held it in 1 quarter. The position peaked at $21K in Q1 2020. 76 funds tracked by Wall St. Rank hold BCLI as of Q2 2020.

  • Macquarie Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2020 after selling out during the quarter.
  • Macquarie Group sold 296 BRAINSTORM CELL THERAPUTC shares in Q2 2020, an estimated $21K.
  • Macquarie Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 1 quarter.
  • Macquarie Group's BRAINSTORM CELL THERAPUTC position peaked at $21K in Q1 2020.
  • 76 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2020.

Based on Macquarie Group's 13F filing for Q2 2020, filed 11 Aug 2020.